Kiplinger released an article in July titled “5 Booming Biotech Stocks to Buy”
It starts off by stating that these stocks are already up over 30% but still have plenty of upside to spare. It references the iShares NASDAQ Biotechnology ETF (NASDAQ: IBB), but which is flat since the article was released.
It’s “5 Booming Biotech Stocks to Buy” are:
- Regeneron Pharmaceuticals (NASDAQ: REGN)
Thanks to strategic partnerships with Sanofi (SNY) and Bayer (BAYRY), Regeneron has ample and expanding exposure to Europe and other international markets.
- Exelixix (NASDAQ: EXEL)
Its top products, Cometriq and Cabometyx, are both based on Exelixis’s flagship compound, cabozantinib; the latter is the market-leading thyroid cancer medicine.
- Vertex Pharmaceuticals (NASDAQ: VRTX)
The company’s flagship product is Trikafta, its new cystic fibrosis (CF) drug that recently launched in the U.S.
- Genmab (NASDAQ: GMAB)
Their monoclonal antibody-based medicine continues to gain market share in Europe and the U.S. with the help of agreements with Seattle Genetics (NASDAQ: SGEN) and BioNTech (NASDAQ: BNTX).
- Emerging BioSolutions (NYSE: EBS)
This is a quickly growing biopharmaceutical company focusing on novel vaccines, treatments, medical devices and other medical countermeasures to tackle public health threats.
Outside of the article, there is an emerging company that needs to be on your radar.
Take a look at Glucose Health, Inc. (OTC Pink: GLUC). The Company manufacturers specialized nutritional beverages for the diabetic-adult consumer under the registered trademark GLUCODOWN®. GLUCODOWN® is infused with a special form of diabetic fiber demonstrated in more than 20 clinical studies to help maintain healthy blood sugar levels and regular digestive health.
Glucose Health, Inc. (OTC Pink: GLUC) just announced unprecedented consumer demand for GLUCODOWN® with 2nd quarter fiscal 2020 revenues increasing by 186% compared to the previous period – Q2 2020 revenues were just short of tripling 2nd quarter 2019 revenues.
What are the sales of this company going to look like when the latest GLUCODOWN® sales numbers from Amazon and Walmart come on the books during Q3 and Q4?
Over the past 12 months, GLUC has seen a range of approximately $.20 – $1.90 per share and with only 12.5 million shares outstanding, GLUC could be the best value in the diabetes space and should be on everybody’s watch list.
EmergingGrowth.com is a leading independent small cap media portal with an extensive history of providing unparalleled content for the Emerging Growth markets and companies. Through its evolution, EmergingGrowth.com found a niche in identifying companies that can be overlooked by the markets due to, among other reasons, trading price or market capitalization. We look for strong management, innovation, strategy, execution, and the overall potential for long- term growth. Aside from being a trusted resource for the Emerging Growth info-seekers, we are well known for discovering undervalued companies and bringing them to the attention of the investment community. Through our parent Company, we also have the ability to facilitate road shows to present your products and services to the most influential investment banks in the space.